Introduction
Institute for Research. This study was designed to improve the quality Previous studies have reported that women with Down's of life of subjects suffering from DS. In fact, some of these patients, syndrome (DS) often have gonadal dysfunction (Hasen et al., due to their handicap, are not able to avoid sexual abuse in their 1980; Hsiang et al., 1987) . Menarche may occur at a later environment, resulting in unwanted pregnancies. Therefore, it is important to increase our knowledge on ovarian function of DS average age in women with DS than in controls (Bellone et al., patients in order to alert the parents to their potential reproductive 1980). Moreover, although the length of menstrual cycles in problems. With regard to informed consent, all parents were clearly DS is within the normal range, a reduction of the reproductive informed about the aim of the study and all signed the acceptance of function is generally accepted. Various authors have found an the protocol.
increased frequency of anovulation or defects of luteal function
The studies were performed in the early follicular phase (days 4- (Tricomi et al., 1964; Scola et al., 1992) ; however, in other 7 of the cycle) after spontaneous menses. At 10.00 a.m., the subjects reports, several reproductive events were documented (Rani received an i.v. injection of pure FSH (Metrodin, Serono, Italy), et al., 1990) . 75 IU dissolved in 1 ml saline solution. Blood samples were collected
In our recent paper, we demonstrated, in a selected regularly during a period of 26 h, at time 0 (basal value) and 2, 4, 6, 8, 10, menstruating group of DS patients, a significantly higher 12, 14, 16, 18, 20, 22, 24 and 26 h after FSH injection. Samples were incidence of anovulation and luteal defects than in controls; centrifuged and plasma stored at -20°C until assayed.
Luteinizing hormone (LH), FSH, prolactin (PRL), oestradiol, profurthermore, both oestradiol and progesterone plasma concen-gesterone, testosterone, androstenedione, dihydroepiandrostenedione 
Results
Saline or FSH i.v. injection did not produce any significant Table I shows the clinical and endocrine characteristics in DS increase of testosterone plasma concentrations in all studied and control patients: no difference for BMI and baseline groups. hormone concentrations was found between the two groups.
No difference among the groups was observed for the Only GH baseline plasma concentrations were found to be ovarian volume as well as for the number and growth of significantly lower in DS group with respect to those observed follicles developed in the cycle studied (data not shown). in controls (P Ͻ 0.05). Figure 1 shows the FSH concentrations after saline or Discussion FSH injection in DS and control patients. FSH baseline concentrations (time 0 h) were slightly, but not significantly
The present study indicates that in a group of normo-ovulatory patients affected by DS, the ovarian sensitivity to exogenous higher in DS group. In patients receiving pure FSH, the FSH AUC was significantly higher than those receiving saline alone.
FSH administration is blunted as compared with the response elicited by exogenous FSH in healthy women in terms of No difference was recorded among FSH-treated patients. The highest FSH plasma values were obtained 2 h after pure i.v. oestradiol production. Previous studies have reported in DS an increased incidence FSH injection and remained significantly higher as compared to the ones found in saline-treated patients until 14 h after the of abnormalities in sexual development (Benda, 1969) ; in addition, pubertal development is delayed in men and women injection. No significant changes in LH values were observed during the study (data not shown).
( Bellone et al., 1980) and ovarian hypoplasia has been described as a constant finding (Benda, 1969) . Based on GH plasma concentrations did not change during the period of study, thus, the AUC-GH values in controls were significthese data, it was believed that oligoamenorrhoea or chronic of anovulation and luteal phase defects (Cento et al., 1996) . It is well known that in early follicular stages of menstrual (pg/ml ϫ 26 h) (%) cycles, the process of follicular recruitment and selection takes Down's syndrome place in a way which is dependent on FSH activity (Zeleznik, FSH 75 IU (n ϭ 6) 8500 Ϯ 7500 a 18 Ϯ 10 c 1981; Zeleznik and Kubik, 1986) . In fact, in this phase FSH Controls Saline (n ϭ 6) 13 393 Ϯ 11.090 a 11 Ϯ 9 b plasma concentrations are slightly elevated, whereas oestradiol FSH 75 IU (n ϭ 6) 49 785 Ϯ 22.857 36 Ϯ 15 concentrations are low (Messinis and Templeton, 1990 in a dose-dependent manner. Conversely, already at the midfollicular phase a 2-fold to 4-fold elevation of circulating FSH anovulation represented the most frequent pattern of menstrual concentrations did not evoke any further increase of oestradiol cycle during the reproductive age of women with DS. However, secretion as compared to that observed in untreated cycles a variable incidence of ovulatory cycles as well as authenticated (Caruso et al., 1993) . These data are of particular interest cases of pregnancy associated with DS have been recently considering that the group of DS patients studied has been reported (Rani et al., 1990) . Scola and Pueschel (1992) found selected on the basis of their normal cyclicity, which excluded that~90% of women with DS have a biphasic pattern of basal all those patients with oligoamenorrhoea, who generally body temperature; Tricomi et al. (1964) observed that no account for a significant percentage of all post-menarchal DS clinical sign of ovulation was documented in 30% of cases, subjects. Moreover, only one patient had a response of oestrawhile in the remaining subjects, 40% had true ovulation and diol to FSH injection in the range of that found in controls. 30% uncertain ovulation. In our recent series, based solely on Thus, although the number of patients studied is small, the difference between the two groups was highly significant. DS patients with regular menses, we found a higher incidence 1994). More recently, it was suggested that ovaries could vary in their sensitivity to GH action in relation to the stage of the human menstrual cycle.
One hypothesis is that GH could enhance ovarian sensitivity by augmenting or stimulating FSH receptors in the early stages of the follicular phase, where a GH involvement in the sensitive feedback relationship between oestradiol and FSH could be possible. In our study, the baseline circulating GH concentrations were significantly lower in DS patients than in control women. Furthermore, neither FSH, nor oestradiol plasma circulating concentrations at baseline were different in respect to controls. Thus, it is conceivable to suggest that the decreased GH secretion may in part account for the blunted sensitivity of ovary to FSH observed in DS patients. However, further studies are needed to elucidate this interesting point. In fact, since it is well known that several endocrino-metabolic features such as insulin secretion or GH/insulin-like growth factor (IGF)/insulin-like growth factor binding protein (IGFBP) axis activity may affect ovarian function, it would be of interest to explore in certain clinical situations, as is the case in DS, the impact of these abnormalities on ovarian function.
In conclusion, the present study confirms and extends the contention that in DS the ovarian function is impaired. In the light of our results, this dysfunction could be in part ascribed to a blunted ovarian sensitivity to gonadotrophins. 
